🎉 M&A multiples are live!
Check it out!

BioStem Technologies Valuation Multiples

Discover revenue and EBITDA valuation multiples for BioStem Technologies and similar public comparables like Mesoblast, Cynata Therapeutics, and Aroa Biosurgery.

BioStem Technologies Overview

About BioStem Technologies

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The Company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AmnioWrap2.


Founded

2006

HQ

United States of America
Employees

20

Financials

LTM Revenue $302M

LTM EBITDA n/a

EV

$215M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

BioStem Technologies Financials

BioStem Technologies has a last 12-month revenue of $302M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, BioStem Technologies achieved revenue of $16.7M and an EBITDA of -$6.9M.

BioStem Technologies expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See BioStem Technologies valuation multiples based on analyst estimates

BioStem Technologies P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $6.9M $16.7M XXX XXX XXX
Gross Profit $2.8M $6.0M XXX XXX XXX
Gross Margin 41% 36% XXX XXX XXX
EBITDA -$6.4M -$6.9M XXX XXX XXX
EBITDA Margin -93% -42% XXX XXX XXX
Net Profit -$1.4M -$7.1M XXX XXX XXX
Net Margin -20% -42% XXX XXX XXX
Net Debt $4.7M $4.3M XXX XXX XXX

Financial data powered by Morningstar, Inc.

BioStem Technologies Stock Performance

As of April 15, 2025, BioStem Technologies's stock price is $13.

BioStem Technologies has current market cap of $210M, and EV of $215M.

See BioStem Technologies trading valuation data

BioStem Technologies Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$215M $210M XXX XXX XXX XXX $1.47

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

BioStem Technologies Valuation Multiples

As of April 15, 2025, BioStem Technologies has market cap of $210M and EV of $215M.

BioStem Technologies's trades at 0.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate BioStem Technologies's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for BioStem Technologies and 10K+ public comps

BioStem Technologies Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $215M XXX XXX XXX
EV/Revenue 12.9x XXX XXX XXX
EV/EBITDA -31.0x XXX XXX XXX
P/E -26.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -57.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get BioStem Technologies Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

BioStem Technologies Valuation Multiples

BioStem Technologies's NTM/LTM revenue growth is -100%

BioStem Technologies's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $1.1M for the same period.

Over next 12 months, BioStem Technologies's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate BioStem Technologies's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for BioStem Technologies and other 10K+ public comps

BioStem Technologies Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 143% XXX XXX XXX XXX
EBITDA Margin -42% XXX XXX XXX XXX
EBITDA Growth 8% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.8M XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue 72% XXX XXX XXX XXX
G&A Expenses to Revenue 60% XXX XXX XXX XXX
R&D Expenses to Revenue 2% XXX XXX XXX XXX
Opex to Revenue 135% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

BioStem Technologies Public Comps

See public comps and valuation multiples for Regenerative Medicine and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Lineage Cell Therapeutics XXX XXX XXX XXX XXX XXX
Arovella Therapeutics XXX XXX XXX XXX XXX XXX
Aroa Biosurgery XXX XXX XXX XXX XXX XXX
Cynata Therapeutics XXX XXX XXX XXX XXX XXX
Mesoblast XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

BioStem Technologies M&A and Investment Activity

BioStem Technologies acquired  XXX companies to date.

Last acquisition by BioStem Technologies was  XXXXXXXX, XXXXX XXXXX XXXXXX . BioStem Technologies acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by BioStem Technologies

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About BioStem Technologies

When was BioStem Technologies founded? BioStem Technologies was founded in 2006.
Where is BioStem Technologies headquartered? BioStem Technologies is headquartered in United States of America.
How many employees does BioStem Technologies have? As of today, BioStem Technologies has 20 employees.
Is BioStem Technologies publicy listed? Yes, BioStem Technologies is a public company listed on PINX.
What is the stock symbol of BioStem Technologies? BioStem Technologies trades under BSEM ticker.
When did BioStem Technologies go public? BioStem Technologies went public in 2008.
Who are competitors of BioStem Technologies? Similar companies to BioStem Technologies include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics.
What is the current market cap of BioStem Technologies? BioStem Technologies's current market cap is $210M
What is the current revenue of BioStem Technologies? BioStem Technologies's last 12-month revenue is $302M.
What is the current EV/Revenue multiple of BioStem Technologies? Current revenue multiple of BioStem Technologies is 0.7x.
What is the current revenue growth of BioStem Technologies? BioStem Technologies revenue growth between 2023 and 2024 was 143%.
Is BioStem Technologies profitable? Yes, BioStem Technologies is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.